First-line serplulimab plus chemotherapy versus chemotherapy alone in small-cell lung cancer patients with brain metastases: a multicenter, prospective cohort study - Top-Institutions - MDSpire

First-line serplulimab plus chemotherapy versus chemotherapy alone in small-cell lung cancer patients with brain metastases: a multicenter, prospective cohort study

  • By

  • Wan Zhang

  • Xiaojun Yang

  • Hualin Chen

  • Xingxiang Pu

  • Reyihanguli Tuohetashi

  • Xuan Wu

  • Zhanhong Xie

  • Di Wu

  • Yongguang Cai

  • Shi Jin

  • Xuli Guo

  • Kaitao Yao

  • Yongfeng Chen

  • Guanming Jiang

  • June 8, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Dongguan People’s Hospital
    Dongguan People’s Hospital

    Dongguan, Guangdong

    Key Differentiators

    • Oncology

  • #2

    Winship Cancer Institute of Emory University School of Medicine
    Winship Cancer Institute of Emory University School of Medicine

    Atlanta, Georgia

    Key Differentiators

    • Oncology

  • #3

    Yale Cancer Center
    Yale Cancer Center

    New Haven, Connecticut

    Key Differentiators

    • Oncology

  • #4

    Catalan Institute of Oncology
    Catalan Institute of Oncology

    Barcelona, Catalonia

    Key Differentiators

    • Oncology

  • #5

    Columbia University Medical Center
    Columbia University Medical Center

    New York, New York

    Key Differentiators

    • Oncology

Original Source(s)

First-line serplulimab plus chemotherapy versus chemotherapy alone in small-cell lung cancer patients with brain metastases: a multicenter, prospective cohort study

  • by Wan Zhang, Xiaojun Yang, Hualin Chen, Xingxiang Pu, Reyihanguli Tuohetashi, Xuan Wu, Zhanhong Xie, Di Wu, Yongguang Cai, Shi Jin, Xuli Guo, Kaitao Yao, Yongfeng Chen, Guanming Jiang

  • June 8, 2026

Related Content

Case Report: Post-transplant lymphoproliferative disorder mimicking Baló’s concentric sclerosis

Tislelizumab combined with gemcitabine as first-line treatment in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma: a single center, single-arm phase 2 trial

Multiple primary head and neck cancers: a scenario-based framework for diagnosis and modern multidisciplinary management